Stock Markets July 2, 2026 06:06 AM

Novartis Secures EU Nod for Itvisma to Treat Older Patients with 5q SMA

One-time gene replacement therapy wins approval for children two years and up, teenagers and adults with bi-allelic SMN1 mutation

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn

Novartis announced that the European Commission has approved Itvisma (onasemnogene abeparvovec) to treat a broad population of patients with 5q spinal muscular atrophy (SMA) who carry a bi-allelic mutation in the SMN1 gene. The approval covers children aged two years and older, teenagers and adults. Itvisma is approved as a single fixed dose gene replacement therapy that does not require adjustment for a patient’s age or body weight. The regulatory decision was supported by data from the registrational STEER study and supportive STRENGTH and STRONG trials, with STEER showing a 2.39-point gain on the Hammersmith Functional Motor Scale sustained through 52 weeks.

Novartis Secures EU Nod for Itvisma to Treat Older Patients with 5q SMA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Itvisma approved in EU for patients aged two years and older, teenagers and adults with bi-allelic SMN1 mutation
  • One-time fixed dose gene replacement therapy - no age or weight dosing adjustments required
  • Approval supported by STEER, STRENGTH and STRONG studies; STEER showed a 2.39-point gain on Hammersmith scale maintained over 52 weeks

Overview

Novartis said the European Commission has approved Itvisma (onasemnogene abeparvovec) for use in patients with 5q spinal muscular atrophy who have a bi-allelic mutation in the survival motor neuron 1 gene. The approval extends to children aged two years and older, as well as teenagers and adults, making Itvisma the first gene replacement therapy authorized in the European Union for this broader SMA population.

Treatment profile

Itvisma is delivered as a one-time, fixed dose intended to address the underlying genetic cause of SMA by replacing the SMN1 gene. According to Novartis, this dosing approach does not require modification based on age or body weight and aims to improve motor function by restoring functional SMN1 gene expression.

Clinical evidence supporting approval

The European clearance is based primarily on results from the registrational STEER study, along with supportive data from the Phase IIIb STRENGTH trial and the Phase I/II STRONG study. In STEER, patients treated with Itvisma experienced a 2.39-point improvement on the Hammersmith Functional Motor Scale, with that benefit maintained over a 52-week observation period. Both the STEER and STRENGTH studies reportedly showed benefit in patients who were treatment-naive as well as those who had received prior therapy.

Reactions

Nicole Gusset, CEO of SMA Europe, described the approval as an important milestone for the SMA community, saying it brings the prospect of an additional treatment choice closer to people and families seeking options that reflect individual needs and circumstances. Patrick Horber, President of International at Novartis, said the authorization enables the company to provide gene replacement therapy options across different stages of SMA in Europe, from newborns to adults, when considered alongside their Zolgensma therapy.

Implications

This authorization positions Itvisma as a new therapeutic option in the EU for a wide age range of SMA patients with a defined genetic diagnosis. The decision rests on the specific clinical measures reported in the cited studies and the durability of benefit observed through one year in STEER.


Key points

  • Itvisma (onasemnogene abeparvovec) approved by the European Commission for children aged two years and older, teenagers and adults with 5q SMA and a bi-allelic SMN1 mutation.
  • The therapy is a one-time fixed dose gene replacement treatment that does not require age or weight-based dose adjustments.
  • Approval was supported by data from the STEER registrational study and supportive STRENGTH and STRONG trials; STEER showed a 2.39-point improvement on the Hammersmith Functional Motor Scale sustained over 52 weeks.

Risks and uncertainties

  • The primary efficacy readout cited was the 2.39-point improvement on the Hammersmith Functional Motor Scale with follow-up reported through 52 weeks; longer-term outcomes beyond this period were not detailed in the information provided.
  • The approval and reported benefits are based on the STEER, STRENGTH and STRONG datasets; the scope of evidence reflected in those studies is the basis for the regulatory decision.

Risks

  • Clinical benefit cited from STEER was maintained through 52 weeks of follow-up; longer-term durability beyond that interval is not reported in the details provided
  • Regulatory approval is based on the STEER registrational study and supportive STRENGTH and STRONG trials, limiting the decision to the scope of those datasets

More from Stock Markets

Premarket: Mixed U.S. Futures as Investors Eye Jobs Data; Select Stocks Move on Earnings, AI Deals and IPO Activity Jul 2, 2026 UBS Keeps ASML at Top of European Tech Picks as AI Spending Bolsters Chip Equipment Demand Jul 2, 2026 AI, Biotech Deals and Reconstitution: Why Small-Caps Have Outpaced Large-Caps in 2026 Jul 2, 2026 Lindsay Shares Jump After Quarterly Profit Tops Reduced Estimates Jul 2, 2026 Great Wall Motor Aims for 3%-5% Share of European Market by 2030 Jul 2, 2026